Portal de Periódicos da CAPES

ORAL POINT OF CARE TEST TO PREDICT HEAD AND NECK SQUAMOUS CELL CANCER

2017; Elsevier BV; Volume: 124; Issue: 3 Linguagem: Inglês

10.1016/j.oooo.2017.05.495

2212-4411

Michael Donovan, Greg Ginn, Elizabeth Franzmann,

Gene expression and cancer classification

Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cause of cancer mortality throughout the world affecting some 50,000 people in the U.S. The ability to detect the disease in a potentially malignant phase and earlier stage should have positive impact on outcome. Previous studies demonstrated that a combined salivary CD44, a tumor-initiating marker, and total protein assay was able to aid in the diagnosis of HNSCC. We sought to understand the performance characteristics of these biomarkers in a prospective population using a qualitative, point-of-care assay (POC) for both CD44 and total protein. We also performed comparative studies on the same samples with a quantitative lab-based test.